Anticoagulation Therapy for Stroke Prevention

Welcome

Read time: 250 mins

Last updated:12th Mar 2020

Welcome to the Anticoagulation Therapy for Stroke Prevention Learning Zone, which introduces the intimate relationship between stroke and atrial fibrillation (AF). Warfarin reduces stroke risk in AF patients, but commonly causes major bleeds and other side effects. The need for regular monitoring and the risk of interactions often makes warfarin difficult to use clinically. Oral non-vitamin K antagonists transformed anticoagulant therapy for non-valvular AF offering improved efficacy and tolerability compared with warfarin.

This Learning Zone reviews the epidemiology, pathophysiology, diagnosis and management of atrial fibrillation, including the latest anticoagulant guidelines, to help you balance the risks and benefits of the various invasive and pharmacological options.

The Learning Zone helps you deliver optimal care and prevent strokes in your patients living with common sustained cardiac arrhythmia.

Click here to register now

Developed by EPG Health for Medthority. This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.